The legalization of marijuana has led to an economic gold rush on the international scale. Between the complete legalization of marijuana in Canada and the legalization of hemp in the US, marijuana business is becoming more and more legitimate. With this rise in business, marijuana stock has followed suit. Since marijuana is still illegal in the majority of the world, CBD, especially CBD derived from hemp is quietly going to make some people millionaires. CBD stocks are new and very risky as you never know what regulation or oversight something as controversial as marijuana and CBD might get but smart choices and research might just make you a lot of money in the not so distant future, if you can get into a stock(s) while they are still new and cheap. I have researched and come up with 3 potential up-and-coming CBD stocks that you’ll want to invest in early 2019, and I can tell you this, you do not want to be the guy who sat and watched CBD stocks skyrocket over the next year and did nothing…
1. Charlotte’s Web Holding Inc. (CWBHF)
Charlotte’s Web Holdings, Inc. engages in the production and distribution of hemp-based, cannabinoid wellness products. Its products is comprised of tinctures, capsules, topical products, powdered supplements, single-use, beverage, and sport and professional products. The company was founded on May 18, 2018 and is headquartered in Boulder, CO.
This stock is like buying future wealth and success. Charlotte’s Web Holding Inc. is the hottest CBD stock in the world right now. Get on it quick. Charlotte’s Web is the nation’s (USA) leader in market share for hemp-derived CBD products. The company’s product is now being sold by over 3,000 retail locations! Not to mention the company’s sales from itsown website and stores. There is no downside to this stock. Retail locations are only going to become more comfortable with carrying marijuana and CBD related items and that only means more business for Charlotte’s Web Holding Inc.
Sales from the company skyrocketed 57% year over year in the third quarter of 2018. In the first nine months of operation, Charlotte’s Web generated nearly $8.7 million in earnings. The company has already been proven and it’s only been nine months! The company doubles its earnings every year and 2019 is looking mighty ripe to be their most lucrative year yet. There is massive amounts of research online for this company. Everyone wants in. You might want to check this one out.
2. Zynerba Pharmaceuticals (ZYNE)
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions such as Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).
This is a rather promising but also risky stock to buy into. The stock is up recently due to the news that Zynerba received a U.S. patent for its cannabidiol (CBD) treatment for Fragile X syndrome. This gave legitimacy to a company that is rather new and doesn’t have a drug on the market just yet. Buying this stock means that you bet on the company’s clinical trial of the new CBD medicine and pray it does well to accompany a stock that is starting to grow exponentially.
The stock has risen 70% but after dropping 30% in 2017 and 70% in 2018. This of course, was before news of the patent. Long-term investors in the stock are most likely happy about the Zynerba Pharmaceuticals news. The stock’s last six months and over the last two years haven’t been promising at all. This has seen it drop 43% from its price of $6.77 that it was sitting at six months ago. While the current price of $5.08 is still short of this, it is good news for investors.
3. CV Sciences Inc. (CVSI):(Plus CBD Oil by CV Sciences Inc)
CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state‐of‐the art production facilities. CV Sciences’ Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences’ Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider’s offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician’s recommendations.
You get the best of both worlds here with CV Sciences. The company specializes in both the product and pharmaceutical aspects of CBD. This is a sure fire method to economic growth. Both sectors of the company’s business is competitive against its competition. I added this stock in because it almost promises a profit as long as the market stays stable. A very low risk stock with potential a long term high reward. The company uses a plethora of technology to make itself more efficient. Every year since 2010 when the company started, it’s grown exponentially. Especially as of late.
CV Sciences generated $34 million in revenue with a profit of $24 million in 2018, which is up 153% from last year. The US’s Farm bill will only continue to benefit the company. CV Sciences also looks to be preparing to fully take advantage of the Hemp Market in the US. CV’s stock was also one of the best performers in 2018. This stock is already proven and 2019 will only be more growth. I would take advantage of this stock sooner rather than later as the stock price will continue to rise.
This article is written by Donald, a young, passionate Cannabis enthusiast. You can follow his Instagram page, here